Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 7, 2005 Rich Duprey	Is Chiron Worth It? The vaccine maker rejects Novartis' bid of $40 a share as inadequate. How much should the pharma pay? Investors, take note.
The Motley Fool September 21, 2005 Rich Duprey	A Shot of Reality for Chiron Novartis warns pharma it's willing to walk away from takeover bid. Does Chiron have the wherewithal to go it alone? Investors, take note.
The Motley Fool October 14, 2005 Rich Duprey	Chiron Ready to Fly Flu vaccine maker readies first shipments as flu season begins and avian flu fears rise.
The Motley Fool April 4, 2006 Rich Duprey	Chiron's Booster Shot Novartis raises its bid for the biotech a second time, appeasing dissident shareholders.
The Motley Fool September 1, 2005 Stephen D. Simpson	Novartis Keeps Gorging Offering to buy the remainder of Chiron for $4.5 billion may up this company's execution risk over the next few quarters. Investors, take note.
The Motley Fool March 16, 2006 Rich Duprey	Chiron's Shareholder Revolt Hedge funds oppose the biotech's buyout by pharmaceutical giant Novartis. Investors, take note.
The Motley Fool October 18, 2005 Rich Duprey	Chiron's Sickly Forecast The flu vaccine maker further reduces its estimated dose production. With its earnings release due next week, perhaps Chiron was simply preparing investors for a jolt.
The Motley Fool June 14, 2005 Rich Duprey	Chiron's Credit Conundrum Standard & Poor's downgrades the biotech's credit rating on seemingly old news. Why now?
The Motley Fool March 3, 2005 Rich Duprey	Chiron Back From the Dead British authorities give vaccine manufacturer the go-ahead to restart facility. Investors can breathe a sigh of relief.
The Motley Fool January 26, 2005 Rich Duprey	Chiron's Earnings Ills Flu vaccine manufacturer expected to report significantly lower profits.
The Motley Fool June 6, 2008 Brian Lawler	Nothing Can Stop Novartis! Swiss pharmaceutical giant Novartis has bucketloads of cash, and apparently, it isn't afraid to use them.
The Motley Fool September 2, 2005 Rich Duprey	Will Flu Vaccine Catch Cold? The CDC says we may have as many as 97 million doses this year, but that's a best-case scenario. This year again, it's Chiron causing the uncertainty.
The Motley Fool July 5, 2006 Rich Duprey	Flu Vaccine Deja Vu The country's largest vaccine maker, Sanofi Aventis, gets an FDA warning letter reminiscent of the 2004 debacle.
The Motley Fool April 8, 2008 Brian Lawler	Novartis Sees More Growth Ahead Novartis makes one of the largest acquisitions in health-care history.
The Motley Fool October 28, 2005 Rich Duprey	Chiron's Bird Flu Contract As Asian bird flu becomes the crisis du jour, this flu vaccine biotech is awarded a hefty contract.
The Motley Fool May 27, 2005 Rich Duprey	Glaxo's Flu Vaccine Booster The drug giant's return could give the U.S. flu vaccine market a shot in the arm.
The Motley Fool May 26, 2005 Brian Gorman	Flu Vaccines' Unhealthy Competition The vaccine business is notoriously tricky. Given the nature of the business, respectable returns are predicated on high volumes. New competitors in the flu-fighting niche could make all companies worse off.
The Motley Fool January 22, 2007 Brian Lawler	Another Busy Year in Store for Novartis Trying to place a value on Novartis is a tough thing to do now with so many important drugs awaiting regulatory review and its addiction to acquisitions and divestitures making financial comparisons between the years tough.
The Motley Fool October 6, 2004 Rich Duprey	Chiron Sneezes, Investors Catch Cold British authorities shut down the pharmaceutical's only U.S. flu vaccine manufacturing facility. This may in fact be an opportunity to scoop up a beleaguered stock at fire sale prices.
Chemistry World July 24, 2009 Matt Wilkinson	Pharma's shot in the arm? As swine flu cases continue to erupt around the globe, the latest financial results from pharmaceutical companies Roche and GlaxoSmithKline reveal that sales of their antiviral drugs have soared.
BusinessWeek January 31, 2005 Arlene Weintraub	Chiron's Flu Aches May Last Awhile Its vaccine rivals are gaining traction -- and its other businesses are just so-so
The Motley Fool October 22, 2004 Rich Duprey	Chiron Reports Profit, But So What? The flu vaccine debacle overshadows the company's profits and earnings.
The Motley Fool December 10, 2004 Rich Duprey	Regulators Quarantine Chiron The FDA sends a warning letter on the heels of a suspension extension by British authorities. Whether shares of the pharmaceutical ultimately finish up or down, the one-two punch from U.S. and British authorities still points to an ailing company.
The Motley Fool January 14, 2005 Rich Duprey	Chiron's Mythical Flu Vaccine The vaccine maker does not know when or if it will be able to start manufacturing again. Investors should pay close attention.
The Motley Fool October 17, 2005 Brian Gorman	Chasing Down Bird Flu Sanofi and GlaxoSmithKline are emerging as the likely winners in the race to produce a bird flu vaccine.
The Motley Fool July 28, 2005 Rich Duprey	Chiron's Tragic Quarter The biotech vaccine maker barely breaks even but boasts of its ability to meet full-year expectations.
The Motley Fool January 19, 2006 Stephen D. Simpson	Novartis Marches On While reported profits are masked by some charges, this Swiss drug company is still delivering the goods. Throw in a solid pipeline and a reasonable valuation, and the stock could still be worth a look for new money in the pharmaceutical space.
The Motley Fool December 18, 2009 Brian Orelli	Swine Flu Just Isn't Bringing Home the Bacon Looks like that one-time boost from sales of swine flu vaccine may not add much to the bottom lines of vaccine makers like GlaxoSmithKline, AstraZeneca, sanofi-aventis, and Novartis.
The Motley Fool June 17, 2005 W.D. Crotty	Biotech's Apple Dumpling Gang Chiron has made a number of financial and planning mistakes in the production of its flu vaccine.
The Motley Fool June 12, 2009 Brian Orelli	Be Careful What You Wish For Do you have the stomach to profit from swine flu?
The Motley Fool October 23, 2009 Brian Orelli	Swine Flu Doesn't Need to Save Novartis The company is looking healthy all on its own.
The Motley Fool February 23, 2010 Brian Orelli	The End of a Swine Flu Era A Food and Drug Administration advisory panel recommended yesterday that next year's seasonal flu vaccine contain the vaccine for the H1N1 virus, aka the swine flu.
The Motley Fool October 23, 2006 Brian Lawler	No Slowing Novartis The Swiss pharmaceutical company shows strength in nearly all its divisions. Novartis looks like a good investment for risk-adverse investors searching for a large-cap pharma stock.
The Motley Fool December 13, 2011 Frank Vinluan	N.C. Novartis Site Is First Cell-Based Flu Vaccine Facility in the Country A Novartis' vaccine facility in North Carolina today became the first facility authorized by the FDA for emergency use during a pandemic.
The Motley Fool March 9, 2005 Rich Duprey	Chiron Bundles Bad News The flu vaccine maker's bad news bonanza can't mask that it's overvalued.
The Motley Fool December 21, 2004 Rich Duprey	Chiron Requests a Second Thought Had the vaccine maker simply issued a press release with the incorrect information, it might be understandable, but investors might feel more at ease if it had gotten it right when it filed documents with the SEC.
BusinessWeek January 9, 2006 Carol Matlack	Preventing The Pandemic France's Sanofi Pasteur is already signing contracts for an avian flu vaccine.
The Motley Fool July 17, 2006 Stephen D. Simpson	Novartis Pays for Its Shopping Spree Expenses from the Chiron acquisition bring down results for the second quarter. Investors, there's a lot to be said for waiting on the right price for even the best stocks out there.
The Motley Fool September 7, 2005 Stephen D. Simpson	Smashing Good Deal, Eh? Glaxo's purchase of Canadian ID Biomedical will seriously augment its vaccine capabilities. Investors, take note.
The Motley Fool January 27, 2010 Brian Orelli	Nice, Novartis, Very Nice CEO Daniel Vasella leaves on a high note.
The Motley Fool March 1, 2011 Brian Orelli	Uncle Sam Gives Novavax a Big Hand Up Cash is everything for a development-stage drugmaker.
Chemistry World November 14, 2013 Phillip Broadwith	Novartis sells off blood diagnostics division Swiss-based company Novartis has agreed to sell off its blood transfusion diagnostics unit to Spanish blood products specialist Grifols for $1.7 billion.
The Motley Fool October 18, 2005 Stephen D. Simpson	More Good News From Novartis This Swiss drug giant continues to post steady growth. Investors, take note.
Chemistry World April 25, 2014 Andy Extance	$25bn-plus trade sharpens pharma giants' focus Three leading pharmaceutical firms are set to exchange business segments valued at over $25 billion, in deals affecting at least 14,000 employees.
The Motley Fool July 16, 2009 Brian Orelli	A Strong Dollar Can Hurt Novartis makes it through a hard quarter.
BusinessWeek October 25, 2004 John Carey	A Booster Shot For Vaccines New technology could speed the development of vaccines and keep the medicine chest stocked.
The Motley Fool December 7, 2004 Brian Gorman	ID Biomedical's Shot in the Arm The company appears well-positioned for the coming years, but it may be best to stay cautious on the company.
The Motley Fool July 14, 2005 Stephen D. Simpson	These Swiss Don't Miss Aside from a hiccup in margins, Novartis' drug business continues to shine. This pharma is a solid middle-of-the-road play with reasonable valuation, a solid pipeline, and a not-so-secret weapon in its Sandoz generics business.
The Motley Fool June 26, 2008 Brian Lawler	Gauging Glaxo's Vaccine Value Surprise! The FDA actually approves Glaxo's new combination children's vaccine without delay.
The Motley Fool March 16, 2005 Cliff Malings	Nice of You to Notice Novartis The Street finally pays attention to a longtime pharma winner on news of a major generic-drug acquisition.